LibraGen signs partnership agreement with Pierre Fabre Medicament R&D LibraGen will use its industrial biocatalysis know-how to carry out research into optimizing the synthesis of a pharmaceutical molecule
09 Jan 2006 -
LibraGen announced that it has signed a partnership agreement with the R&D department of Pierre Fabre Medicament, France's second largest independent pharmaceutical company. Under the terms of the agreement, LibraGen will use enzymatic technologies to optimize the synthesis of a molecule which is the main active ingredient of one of Pierre Fabre's medicines. This enzymatic production process bypasses
the need for several stages of chemical synthesis, thus optimizing production costs and significantly improving environmental impact.
Top
Contact
Print version
PDF version
Send article
RSS-Feed